Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01222546
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : June 23, 2014
Information provided by (Responsible Party):
Chugai Pharma Europe Ltd.

Brief Summary:
This is an open-label, multi-center, dose-escalation Phase I study to evaluate safety, pharmacokinetics and activity of CH5132799 administered orally as a single agent in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: CH5132799 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors
Study Start Date : August 2010
Actual Primary Completion Date : November 2012
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Experimental: CH5132799 Drug: CH5132799

Primary Outcome Measures :
  1. Occurrence of dose limiting toxicities [ Time Frame: Upon completion of the study ]
  2. Preliminary anti-tumour activity [ Time Frame: Upon completion of the study ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetics of CH5132799 [ Time Frame: Upon completion of the study ]
  2. To characterise the pharmacodynamic effect of CH5132799 in surrogate tissues [ Time Frame: Upon completion of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provision of signed written informed consent.
  2. Histologically or cytologically confirmed diagnosis of advanced solid tumor.
  3. Age ≥ 18 years.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  5. Life expectancy of ≥ 12 weeks.
  6. Disease measurability:

    Patients must have a measurable - as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1 - and/or evaluable disease.

  7. Paraffin-embedded archival tumor tissue available. Fresh biopsies will be required if no paraffin embedded tumor tissues available.
  8. Adequate bone marrow function.
  9. Adequate cardiac function: Patient should have Left Ventricular Ejection Fraction (LVEF) of ≥ 50% as determined by echocardiography (ECHO) or Multi Gated Acquisition (MUGA) scans.
  10. Adequate liver function.
  11. Adequate renal function.
  12. Adequate adrenal function assessed by baseline cortisol of > 200 nmol/L
  13. Ability to comply with protocol requirements.
  14. Female patients must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Male patients who have been sterilized must agree to use a barrier method of contraception. Male subjects must also commit to use a barrier method of contraception until at least 3 months after the end of study treatment.
  15. Female patients of child-bearing potential must have a negative serum pregnancy test within the seven days prior to the first study drug administration.

Exclusion Criteria:

  1. History of allergic reactions attributed to components of the formulated product.
  2. Inability to swallow oral medications or impaired gastrointestinal absorption due to active inflammatory bowel disease.
  3. Known Central Nervous System (CNS) metastases or leptomeningeal metastases will be eligible only if it could be radiologically demonstrated that there is no CNS disease progression during the 3 months prior to the study
  4. Known active or uncontrolled pulmonary dysfunction.
  5. Uncontrolled hypertension
  6. Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy for bone pain), or immunotherapy within 28 days of first receipt of study drug (within 6 weeks for nitrosoureas and mitomycin C). Hormone therapy within 14 days of first receipt of study drug, with exception of prostate cancer if indicated.
  7. Prior toxicities from chemotherapy or radiotherapy which have not regressed to Grade ≤ 1 severity - National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0).
  8. Type 1 or 2 diabetes mellitus requiring regular medication and/or a fasting plasma glucose (FPG) ≥ 120 mg/dL (or 6.6 mmol/dL) at screening.
  9. Increased QTc interval (QTc > 450 ms for male; > 460 ms for female).
  10. History of heart failure, refractory hypokalemia to adequate supplementation, family history of long QT syndrome or other risk factors for "Torsades de Pointes", and/or the use of concomitant medications that prolong the QT/QTc interval.
  11. Prior corticosteroid therapy within 14 days of first receipt of study drug.
  12. Treatment with any investigational agent within 28 days of first receipt of study drug.
  13. Acute or chronic infection. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding or any other medical condition that, in the opinion of the investigator, contraindicates the use of an investigational drug, or will impose excessive risk to the patient.
  14. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
  15. History of clinically significant bowel disease including abdominal fistula, gastro-intestinal perforation, and diverticulitis.
  16. Major surgery within 28 days of first receipt of study drug.
  17. Pregnant or lactating women
  18. Altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01222546

United Kingdom
Investigator Sites
London, Leeds, United Kingdom
Sponsors and Collaborators
Chugai Pharma Europe Ltd.

Responsible Party: Chugai Pharma Europe Ltd. Identifier: NCT01222546     History of Changes
Other Study ID Numbers: PA-001EU
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: June 23, 2014
Last Verified: June 2014